阿帕替尼联合化疗治疗晚期胃癌患者的临床疗效观察

Efficacy of apatinib combined with chemotherapy in the treatment of advanced gastric cancer

目的探讨阿帕替尼联合化疗治疗晚期胃癌患者的疗效及不良反应。方法选取2016年2月至2018年2月间保山市腾冲市人民医院收治的60例晚期胃癌患者,采用随机娄表法分为联合治疗组和基础治疗组,每组30例。联合治疗组采用阿帕替尼联合化疗治疗,基础治疗组采用基础化疗治疗,比较两组患者的临床疗效和不良反应发生情况。结果联合治疗组患者总缓解率为80. 0%(24/30),高于基础治疗组的63. 3%(19/30),差异有统计学意义(P <0. 05)。联合治疗组患者高血压和蛋白尿发生率为36. 7%(11/30)和16. 7%(5/30),均高于基础治疗组的0. 0%和0. 0%,差异均有统计学意义(均P <0. 05);但两组患者的恶心呕吐、口腔黏膜炎、骨髓抑制和肝功能损害发生率比较,差异无统计学意义(P> 0. 05)。结论阿帕替尼联合化疗治疗晚期胃癌患者的临床疗效较好,虽然会提升高血压和蛋白尿发生率,但患者能耐受,值得在临床推广应用。

Objective To explore the efficacy and adverse reactions of apatinib combined with chemotherapy in the treatment of advanced gastric cancer. Methods A total of 60 patients with advanced gastric cancer treated at Tengchong People＇s Hospital from February 2016 to February 2018 were selected by method of cluster random sampling. These patients were divided into a combined chemotherapy group and a basic chemotherapy group according to the treatment methods with 30 patients in each group. The combined chemotherapy group received apatinib combined chemotherapy and the basic chemotherapy group received basic therapy group. The clinical efficacy and adverse reactions were analyzed and compared between the two groups. Results The total remission rate was 80. 0%（ 24/30） for the combined treatment group which was significantly higher than 63. 3%（ 19/30） of the basic treatment group（ P〈0. 05）. The incidence of hypertension and proteinuria was 36. 7%（ 11/30） and 16. 7%（ 5/30） respectively for the combined chemotherapy which was significantly higher than 0. 0% and 0. 0% respectively of the basic treatment group（ all P〈0. 05）. However,there was no significant difference in the incidence of nausea and vomiting,oral mucositis,myelosuppression and liver dysfunction between the two groups（ P〉0. 05）. Conclusion The efficacy of apatinib combined with chemotherapy in the treatment of advanced gastric cancer is more significant than basic chemotherapy. Although it can improve the incidences of hypertension and proteinuria,it can be tolerated. Thus,it is worthy of clinical promotion and application.